Pharma Pulse 4/25/25: Roche in ‘Very, Very Good Position’ To Weather Trump Tariffs but M&A May Suffer, Thermo Fisher to Invest Addlitional $2 Billion In US To Boost Manufacturing

Roche in ‘Very, Very Good Position’ To Weather Trump Tariffs but M&A May Suffer

Roche expects to weather the financial impact of Trump-era tariffs due to its strategic US manufacturing shifts and global investments, though M&A activity may slow as the industry assesses the tariffs’ broader implications.

Thermo Fisher To Invest Addl. $2 Bln In US To Boost Manufacturing

Thermo Fisher plans to invest an additional $2 billion in the United States over four years to expand manufacturing and R&D, reinforcing its commitment to American innovation and a resilient healthcare supply chain.

Effectiveness Not Volume: Q&A with Pooja Lal

In an interview with Pharmaceutical Executive, Pooja Lal, VP at Veeva Systems, emphasizes that pharma companies should use AI to enhance content effectiveness and speed—especially through early collaboration with reviewers and automation of compliance checks—rather than simply increasing volume, with MLR pre-review emerging as a high-impact starting point.

Merck lowers profit outlook, partly due to $200 million expected tariff hit

Merck lowered its 2025 profit forecast due to a $200 million expected tariff hit and a licensing charge but reported stronger-than-expected Q1 earnings driven by oncology and animal health sales, while facing challenges in China and planning significant US manufacturing investments to mitigate future tariff impacts.

Measles on the Move: Guidance for Pharmacists During Outbreaks

Amid a surge in US measles cases, pharmacists are urged to educate patients on prevention, vaccination, and updated outbreak guidance, especially for unvaccinated individuals.